Scarica l'app Stockscreener
2.055
5.69%
0.105
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - Insider Monkey
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings - Stock Titan
Diane E. Sullivan converts 89,312 RSUs at Lexicon Pharmaceuticals (LXRX) - Stock Titan
[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Lexicon Pharmaceuticals (LXRX) director exercises 89,312 RSUs into shares - Stock Titan
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 restricted stock units into common stock - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 RSUs into common stock, boosts stake - Stock Titan
LXRX: Pivotal HCM trial nears completion as pipeline and partnerships drive transformation - TradingView
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates - Yahoo Finance
New Type 1 diabetes drug data from Lexicon at ADA 2026 meeting - Stock Titan
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions - The Manila Times
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon (LXRX) Q1 2026 Earnings Transcript - The Globe and Mail
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharma schedules Jefferies healthcare fireside chat for June 4 - Stock Titan
SA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRX - Seeking Alpha
Lexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade) (NASDAQ:LXRX) - Seeking Alpha
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
LXRX Stock Price, Quote & Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
5 Best Penny Stocks to Buy for Long Term - Insider Monkey
Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility - MSN
A Look At Lexicon Pharmaceuticals (LXRX) Valuation After Improved Q1 Revenue And Narrowed Net Loss - Sahm
Lexicon Pharmaceuticals: up to 50 percent of type 2 diabetes patients affected by painful neuropathy - Traders Union
Lexicon Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-05-15 - Seeking Alpha
Navigating Life with Hypertrophic Cardiomyopathy - GlobeNewswire Inc.
Lexicon Pharmaceuticals (LXRX) Is Up 52.5% After Q1 Loss Narrows And Revenue JumpsHas The Bull Case Changed? - simplywall.st
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed - Yahoo Finance
Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat - Traders Union
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - Herald and News
Fireside chat at Nasdaq HQ: Lexicon joins H.C. Wainwright investor event May 19 - Stock Titan
LXRX Maintained by Citigroup -- Price Target Raised to $3.10 - GuruFocus
$Lexicon Pharmaceuticals (LXRX.US)$ 🚀🚀🚀🚀🚀🤩🤩🤩🤩🤩 - Moomoo
Citigroup Issues Positive Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price - MarketBeat
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $3.1 - Moomoo
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones - Yahoo Finance
1.79%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):